Skip to main content
Signal8

VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats

$VNRXPress releaseMay 6, 2026, 8:17 AM ET

VolitionRx submitted a clinical manuscript for its Nu.Q Vet Feline test, reporting 86% detection of feline lymphomas with 97% specificity. Publication of the study is expected to unlock a $5 million milestone payment and validates the technology for a new species.

Key figures

Sensitivity
86%
Specificity
97%
Cancer risk cats
1 in 5
Milestone payment
$5 million
Us pet cat population
73.8 million
Us senior cat population
over 18 million
Na vet oncology market 2025
$1.77 billion

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.